DaVita Slides as Investors Appear to De-Risk Ahead of Earnings

DaVita Inc. (DVA) is down 5.0% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely explanation is pre-earnings de-risking rather than a clearly disclosed negative company event. DaVita announced on October 19 that it will report third-quarter 2026 results on October 29, and recent public company channels do not show a fresh adverse filing or guidance cut that would obviously explain a one-day drop. This could be because traders are locking in gains after a strong run earlier this year and repositioning ahead of the next earnings update. ([investors.davita.com](https://investors.davita.com/news-releases/?o=1185&sessionGUID=383dd8bb-4517-e0c5-8d1c-a69614782588&webSyncID=bd72a83e-91ad-a982-a00b-dac625683bb6&utm_source=openai))

Details:

DaVita’s investor site listed a new item on October 19 scheduling its third-quarter 2026 investor conference call for October 29 after the market closes. ([investors.davita.com](https://investors.davita.com/news-releases/?o=1185&sessionGUID=383dd8bb-4517-e0c5-8d1c-a69614782588&webSyncID=bd72a83e-91ad-a982-a00b-dac625683bb6&utm_source=openai))

The company’s recent investor news flow has been operationally positive, including research presentations at ASN Kidney Week on October 15, with no obvious same-day negative announcement visible in the latest releases. ([investors.davita.com](https://investors.davita.com/2026-10-15-davita-brings-new-clinical-research-to-asn-kidney-week-2026-advancing-evidence-for-the-next-era-of-kidney-care/?utm_source=openai))

The SEC filings page visible through the investor site mainly shows routine filings in recent weeks, such as insider Form 4 disclosures, rather than a newly posted material warning. ([investors.davita.com](https://investors.davita.com/sec-filings/?cat=1&filer=Ticker%3ADVA&utm_source=openai))

The stock had already been volatile, rising 4.57% on October 15 and entering October 20 up 64.6% year to date, which supports the idea of profit-taking ahead of earnings. ([marketbeat.com](https://www.marketbeat.com/stocks/NYSE/DVA/chart/?utm_source=openai))

Sources:

DaVita Investor Relations, SEC, MarketBeat

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$DVA Insider Trading Activity

$DVA insiders have traded $DVA stock on the open market 9 times in the past 6 months. Of those trades, 0 have been purchases and 9 have been sales.

Here’s a breakdown of recent trading of $DVA stock by insiders over the last 6 months:

HATHAWAY INC BERKSHIRE has made 0 purchases and 2 sales selling 1,403,356 shares for an estimated $219,377,971.
JAVIER RODRIGUEZ (Chief Executive Officer) has made 0 purchases and 2 sales selling 69,407 shares for an estimated $14,532,108.
DAVID PAUL MAUGHAN (Chief Operating Officer, DKC) has made 0 purchases and 2 sales selling 20,529 shares for an estimated $4,089,742.
KATHLEEN ALYCE WATERS (Chief Legal & Pub. Affairs Off) has made 0 purchases and 2 sales selling 15,405 shares for an estimated $3,210,376.
JAMES O HEARTY (Chief Compliance Officer) sold 15,000 shares for an estimated $2,909,745

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$DVA Hedge Fund Activity

We have seen 295 institutional investors add shares of $DVA stock to their portfolio, and 283 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

BERKSHIRE HATHAWAY INC removed 1,220,376 shares (-4.1%) from their portfolio in Q2 2026, for an estimated $271,509,252
BANK OF AMERICA CORP /DE/ added 410,940 shares (+170.5%) to their portfolio in Q2 2026, for an estimated $91,425,931
NEUBERGER BERMAN GROUP LLC added 393,492 shares (+74.0%) to their portfolio in Q2 2026, for an estimated $87,544,100
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 365,569 shares (+inf%) to their portfolio in Q2 2026, for an estimated $81,331,791
WOODLINE PARTNERS LP removed 350,172 shares (-77.3%) from their portfolio in Q2 2026, for an estimated $77,906,266
UBS GROUP AG removed 345,349 shares (-53.1%) from their portfolio in Q2 2026, for an estimated $76,833,245
FREESTONE GROVE PARTNERS LP removed 315,157 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $70,116,129

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$DVA Government Contracts

We have seen $181,090,169 of award payments to $DVA over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

EXPRESS REPORT: FY 26 NOVEMBER NDSC EXPRESS REPORT: $121,425,309
EXPRESS REPORT: FY 26 OCTOBER NDSC EXPRESS REPORT: $26,893,447
ON-SITE DIALYSIS SERVICES: $1,145,928

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$DVA Analyst Ratings

Wall Street analysts have issued reports on $DVA in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Deutsche Bank issued a "Buy" rating on 05/06/2026

To track analyst ratings and price targets for $DVA, check out Quiver Quantitative's $DVA forecast page.

$DVA Price Targets

Multiple analysts have issued price targets for $DVA recently. We have seen 5 analysts offer price targets for $DVA in the last 6 months, with a median target of $218.0.

Here are some recent targets:

Andrew Mok from Barclays set a target price of $218.0 on 07/09/2026
Ryan Langston from TD Cowen set a target price of $201.0 on 05/11/2026
David Macdonald from Truist Securities set a target price of $205.0 on 05/08/2026
A.J. Rice from UBS set a target price of $235.0 on 05/07/2026
Pito Chickering from Deutsche Bank set a target price of $220.0 on 05/06/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.